BVXP - BIOVENTIX - Share Chat
Bioventix plc is a UK-based developer and supplier of high-affinity recombinant monoclonal antibodies primarily for the global in-vitro diagnostics (IVD) market. Listed on AIM, the company’s core business model revolves around licensing its proprietary antibodies, such as those for cardiac markers (e.g., Troponin), Vitamin D, and thyroid function, to major international diagnostic companies.
Revenue is predominantly derived from long-term royalty agreements based on the sale of diagnostic tests incorporating its antibodies. Bioventix’s competitive edge lies in its recombinant technology, which delivers superior specificity, sensitivity, and batch-to-batch consistency, critical for high-volume IVD applications. The company is known for its strong profit margins and cash generation, making it an attractive niche player in the life sciences sector with growth driven by expanding demand for diagnostic testing.
Chat about BIOVENTIX
Bioventix (BVXP) continues to deliver impressive results and a strong dividend. What are your thoughts on their recent performance? Do you believe their unique antibody technology can drive further growth, particularly with new licensing opportunities? Keen to hear if you see more upside or current levels.